Litigation Details for CELGENE CORPORATION v. PAR PHARMACEUTICAL, INC. (D.N.J. 2017)
✉ Email this page to a colleague
CELGENE CORPORATION v. PAR PHARMACEUTICAL, INC. (D.N.J. 2017)
| Docket | ⤷ Try a Trial | Date Filed | 2017-05-04 |
| Court | District Court, D. New Jersey | Date Terminated | 2019-02-06 |
| Cause | 35:271 Patent Infringement | Assigned To | Esther Salas |
| Jury Demand | None | Referred To | Michael A. Hammer |
| Patents | 6,045,501; 6,315,720; 6,561,977; 6,755,784; 8,198,262; 8,315,886; 8,626,531; 8,673,939; 8,735,428; 8,828,427; 8,927,592 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in CELGENE CORPORATION v. PAR PHARMACEUTICAL, INC.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for CELGENE CORPORATION v. PAR PHARMACEUTICAL, INC. (D.N.J. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-11-14 | 122 | Celgene’s closely-related U.S. Patent No. 6,045,501 (“the ’501 patent”), where the PTAB concluded ….S. Patent No. 8,626,531 B1 ’720 patent U.S. Patent No. 6,315,720 B1 ’784 patent ….S. Patent No. 6,755,784 B2 ’886 patent U.S. Patent No. 8,315,886 B2 ’939 patent …MOT patents”); (2) the ’427 formulation patent; and (3) ’720, ’977, ’784, ’886, and ’531 patents, which…. The MOT Patents (’262, ’939, and ’428 Patents) The asserted MOT patent claims are generally | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
